Analyst Calls: Barclays Hits NuScale, Loop Cuts Apple to Hold and BlackRock Wins a TD Cowen Upgrade
Barclays cuts NuScale to Underweight, Loop Capital downgrades Apple, and TD Cowen upgrades BlackRock to Buy in a morning of 42 analyst calls. Plus the AI-infrastructure initiations & what to watch.
Wall Street's research desks delivered 42 rating and target changes Tuesday, Oct. 20, tilted heavily bullish: 33 Buy-equivalent calls, five Hold-equivalent and four Sell-equivalent. The headline cuts are Barclays on NuScale Power, Loop Capital on Apple and JPMorgan on EyePoint, while TD Cowen upgraded BlackRock to Buy. Initiations clustered around AI data-center infrastructure. Stocks trade normally today.
Downgrades and bearish calls
Barclays downgraded NuScale to Underweight and cut its target to $5 from $11, citing commercial execution and project delays. NuScale was down 7.4% premarket at $5.27, per Benzinga. Loop Capital moved Apple to Hold from Buy and cut its target to $330 from $370 on weakening iPhone demand and an elevated valuation. JPMorgan downgraded EyePoint after failed Phase 3 results for Duravyu in wet AMD, and HSBC reiterated Reduce on CoreWeave, warning that projected 8.9% returns on invested capital fall below borrowing costs.
| Company | Ticker | Firm | Rating change | Price target | Why |
|---|---|---|---|---|---|
| Apple | AAPL | Loop Capital | Buy to Hold | $330 from $370 | Weakening iPhone demand and elevated valuation |
| NuScale Power | SMR | Barclays | Equal Weight to Underweight | $5 from $11 | Commercial execution and project delays |
| EyePoint | EYPT | JPMorgan | Neutral to Underweight | Not stated | Failed Phase 3 results for Duravyu in wet AMD |
| Zoetis | ZTS | Jefferies | Buy to Hold | $83 from $103 | Not stated |
| Werner Enterprises | WERN | Baird | Outperform to Neutral | $32 from $43 | Not stated |
| Heartland Express | HTLD | Baird | Outperform to Neutral | $12 from $16 | Not stated |
| RELX | RELX | Citi | Buy to Neutral | 3,125p from 2,870p (London listing) | Not stated |
| Vodafone | VOD | Barclays | Equal Weight to Underweight | Not stated | Not stated |
Upgrades
TD Cowen's BlackRock upgrade carried the biggest target move in dollar terms, to $1,405 from $1,212. Two upgrades lean on AI power and infrastructure demand: BTIG on American Electric Power and Wells Fargo on Venture Global, whose target jumped to $21 from $15. Raymond James kept Akamai's $170 target but moved to Strong Buy, calling the recent AI-sector sell-off an opportunity.
| Company | Ticker | Firm | Rating change | Price target | Why |
|---|---|---|---|---|---|
| BlackRock | BLK | TD Cowen | Hold to Buy | $1,405 from $1,212 | Accelerating earnings growth |
| Venture Global | VG | Wells Fargo | Equal Weight to Overweight | $21 from $15 | AI data center opportunities and improving leverage |
| American Electric Power | AEP | BTIG | Neutral to Buy | $147 | Data center electricity demand |
| Akamai | AKAM | Raymond James | Outperform to Strong Buy | $170 (unchanged) | Calls the recent AI-sector sell-off an opportunity |
| Healthcare Realty Trust | HR | Deutsche Bank | Hold to Buy | $23 from $18 | Not stated |
| Trex | TREX | Stifel | Hold to Buy | $55 | Attractive valuation |
| Arhaus | ARHS | Piper Sandler | Neutral to Overweight | $13 | Improving sales and margin recovery |
| Liberty Global | LBTYA | New Street | Neutral to Buy | $14 | Significant undervaluation despite elevated risk |
New coverage
Data-center demand was the common thread. JPMorgan began nVent Electric at Overweight and Cantor Fitzgerald started Modine at Overweight, both citing data-center cooling opportunities. ADARx Pharmaceuticals drew four initiations at once, from Morgan Stanley, JPMorgan, UBS and TD Cowen.
| Company | Ticker | Firm | Rating change | Price target | Why |
|---|---|---|---|---|---|
| nVent Electric | NVT | JPMorgan | Initiates Overweight | $167 | Data center and liquid-cooling opportunities |
| Modine Manufacturing | MOD | Cantor Fitzgerald | Initiates Overweight | $275 | Data center cooling demand |
| Thomson Reuters | TRI | Jefferies | Initiates Buy | $130 | AI products, revenue growth and operating leverage |
| SiTime | SITM | Rosenblatt | Initiates Buy | $750 | Structural semiconductor growth |
| Restaurant Brands International | QSR | Mizuho | Initiates Outperform | $85 | Burger King recovery and international growth |
| News Corp | NWSA | Raymond James | Initiates Outperform | $35 | Discounted valuation |
| Concentra | CON | Stephens | Initiates Overweight | $45 | Occupational healthcare business |
| Artivion | AORT | Jefferies | Initiates Buy | $31 | New product launches and margin expansion |
| Ford | F | Oxcap | Initiates Overweight | $15.50 | Not stated |
| ADARx Pharmaceuticals | ADRX | Morgan Stanley, JPMorgan, UBS, TD Cowen | Initiations at Overweight or Buy | $32 (Morgan Stanley), $38 (JPMorgan), $35 (UBS) | TD Cowen initiated at Buy; target not stated |
| Climb Bio | CLYM | Deutsche Bank | Initiates Buy | $28 | Not stated |
Reiterations and target changes
BTIG raised its Rapport Therapeutics target to $89 from $75 after positive Phase 2 results; the stock was up 22.4% premarket at $35.00, per StockAnalysis. BMO raised Alphabet to $480 from $465 and kept it a Top Pick even while projecting $325B in 2027 capital spending. Cantor Fitzgerald reiterated Overweight on SpaceX ahead of its third-quarter report after the close.
| Company | Ticker | Firm | Rating | Price target | Why |
|---|---|---|---|---|---|
| Alphabet | GOOGL | BMO | Outperform, Top Pick | $480 from $465 | Raised target despite projecting $325B in 2027 capital spending |
| Rapport Therapeutics | RAPP | BTIG | Buy | $89 from $75 | Positive Phase 2 results |
| Atlassian | TEAM | BTIG | Buy | $260 from $230 | Not stated |
| Amplitude | AMPL | BTIG | Buy | $17 from $13 | Not stated |
| Cardinal Health | CAH | Mizuho | Outperform | $280 from $250 | Not stated |
| Gilead Sciences | GILD | Bank of America | Buy | $172 from $168 | Not stated |
| Seagate | STX | Morgan Stanley | Overweight, Top Pick reinstated | $1,200 from $1,187 | Not stated |
| Advanced Micro Devices | AMD | Wedbush | Outperform | $600 | Reiterated |
| Microsoft | MSFT | BMO | Outperform | $600 | Reiterated |
| Meta Platforms | META | Rosenblatt | Buy | $886 | Reiterated |
| Nvidia | NVDA | Piper Sandler | Overweight | Not stated | Notes mixed investor sentiment and limited near-term catalysts |
| Western Digital | WDC | Morgan Stanley | Overweight | Not stated | Favors the stock tactically ahead of earnings |
| SpaceX | SPCX | Cantor Fitzgerald | Overweight | Not stated | Expects stronger 2027 performance and expanding handset ambitions ahead of Q3 earnings |
| American Tower | AMT | Bernstein | Outperform | $212 from $214 | Lowered target |
| CoreWeave | CRWV | HSBC | Reduce | $39 (unchanged) | Warns projected 8.9% returns on invested capital fall below borrowing costs |
What else is on the calendar
Netflix, SpaceX, United Airlines, Capital One, Chubb, Alaska Air and Intuitive Surgical report after the close today, and Meta and Tesla report Wednesday after the close. The Fed meets Oct. 27 to 28, and CME FedWatch shows roughly an 83% probability of no change, as reported by Beinsure. Housing starts and permits are also due today; no release time was sourced.
Readers also read
T-Mobile Plunges 13% as SpaceX's Reported $8 Billion Spectrum Deal Rattles AT&T and Verizon
ResearchMicron Is Stalling on Peak Fears, but Memory Prices Haven't Gotten the Memo
ResearchGoogle Gives Gemini Its Own Email Address and a Job: What the Workplace Agent Means for Alphabet Stock
RecapWeek Ahead: Fed Minutes, Five Fed Speakers and the First Big Earnings of Q3 Season
MarketCatalyst LLC is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
